Supplementary Appendix for

BNT162b2 XBB1.5-adapted Vaccine and COVID-19 Hospital Admissions and Ambulatory Visits in US Adults

Sara Y. Tartof, PhD; Jeff M. Slezak, MS; Timothy B. Frankland, MA; Laura Puzniak, PhD;

Vennis Hong, MPH; Bradley K. Ackerson, MD; Julie A Stern, MPH; Sarah Simmons;

Luis Jodar, PhD; John M. McLaughlin, PhD

Supplement

A48.1	LEGIONNAIRES' DISEASE
B34.2	CORONAVIRUS INFECTION, UNSPECIFIED
B44.0	INVASIVE PULMONARY ASPERGILLOSIS
B97.29	OTH CORONAVIRUS AS THE CAUSE OF DISEASES CLASSD ELSWHR
J00	ACUTE NASOPHARYNGITIS (COMMON COLD)
J01.00	ACUTE MAXILLARY SINUSITIS, UNSPECIFIED
J01.10	ACUTE FRONTAL SINUSITIS, UNSPECIFIED
J01.20	ACUTE ETHMOIDAL SINUSITIS, UNSPECIFIED
J01.30	ACUTE SPHENOIDAL SINUSITIS, UNSPECIFIED
J01.40	ACUTE PANSINUSITIS, UNSPECIFIED
J01.80	OTHER ACUTE SINUSITIS
J01.90	ACUTE SINUSITIS, UNSPECIFIED
J02.0	STREPTOCOCCAL PHARYNGITIS
J02.8	ACUTE PHARYNGITIS DUE TO OTHER SPECIFIED ORGANISMS
J02.9	ACUTE PHARYNGITIS, UNSPECIFIED
J03.00	ACUTE STREPTOCOCCAL TONSILLITIS, UNSPECIFIED
J03.90	ACUTE TONSILLITIS, UNSPECIFIED
J04.0	ACUTE LARYNGITIS
J04.10	ACUTE TRACHEITIS WITHOUT OBSTRUCTION
J05.0	ACUTE OBSTRUCTIVE LARYNGITIS (CROUP)
J05.10	ACUTE EPIGLOTTITIS WITHOUT OBSTRUCTION
J06.0	ACUTE LARYNGOPHARYNGITIS
J06.9	ACUTE UPPER RESPIRATORY INFECTION, UNSPECIFIED
J09.X1	INFLUENZA DUE TO IDENT NOVEL INFLUENZA A VIRUS W PNEUMONIA
J09.X2	FLU DUE TO IDENT NOVEL INFLUENZA A VIRUS W OTH RESP MANIFEST
J10.00	FLU DUE TO OTH IDENT FLU VIRUS W UNSP TYPE OF PNEUMONIA
J10.01	FLU DUE TO OTH IDENT FLU VIRUS W SAME OTH IDENT FLU VIRUS PN
J10.08	INFLUENZA DUE TO OTH IDENT INFLUENZA VIRUS W OTH PNEUMONIA
J10.1	FLU DUE TO OTH IDENT INFLUENZA VIRUS W OTH RESP MANIFEST
J10.2	INFLUENZA DUE TO OTH IDENT INFLUENZA VIRUS W GI MANIFEST
J11.00	FLU DUE TO UNIDENTIFIED FLU VIRUS W UNSP TYPE OF PNEUMONIA
J11.08	FLU DUE TO UNIDENTIFIED FLU VIRUS W SPECIFIED PNEUMONIA
J11.1	FLU DUE TO UNIDENTIFIED INFLUENZA VIRUS W OTH RESP MANIFEST
J12.1	RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA
J12.2	PARAINFLUENZA VIRUS PNEUMONIA
J12.3	HUMAN METAPNEUMOVIRUS PNEUMONIA
J12.81	PNEUMONIA DUE TO SARS-ASSOCIATED CORONAVIRUS

 Table S1. Acute Respiratory Infection Codes, October 10, 2023 through December 10, 2023

J12.82	PNEUMONIA DUE TO CORONAVIRUS DISEASE 2019
J12.89	OTHER VIRAL PNEUMONIA
J12.9	VIRAL PNEUMONIA, UNSPECIFIED
J13	PNEUMONIA DUE TO STREPTOCOCCUS PNEUMONIAE
J14	PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE
J15.0	PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE
J15.1	PNEUMONIA DUE TO PSEUDOMONAS
J15.20	PNEUMONIA DUE TO STAPHYLOCOCCUS, UNSPECIFIED
J15.211	PNEUMONIA DUE TO METHICILLIN SUSCEP STAPH
J15.212	PNEUMONIA DUE TO METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS
J15.4	PNEUMONIA DUE TO OTHER STREPTOCOCCI
J15.5	PNEUMONIA DUE TO ESCHERICHIA COLI
J15.6	PNEUMONIA DUE TO OTHER AEROBIC GRAM-NEGATIVE BACTERIA
J15.7	PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE
J15.8	PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA
J15.9	UNSPECIFIED BACTERIAL PNEUMONIA
J16.8	PNEUMONIA DUE TO OTHER SPECIFIED INFECTIOUS ORGANISMS
J18.0	BRONCHOPNEUMONIA, UNSPECIFIED ORGANISM
J18.1	LOBAR PNEUMONIA, UNSPECIFIED ORGANISM
J18.8	OTHER PNEUMONIA, UNSPECIFIED ORGANISM
J18.9	PNEUMONIA, UNSPECIFIED ORGANISM
J20.2	ACUTE BRONCHITIS DUE TO STREPTOCOCCUS
J20.5	ACUTE BRONCHITIS DUE TO RESPIRATORY SYNCYTIAL VIRUS
J20.6	ACUTE BRONCHITIS DUE TO RHINOVIRUS
J20.8	ACUTE BRONCHITIS DUE TO OTHER SPECIFIED ORGANISMS
J20.9	ACUTE BRONCHITIS, UNSPECIFIED
J22	UNSPECIFIED ACUTE LOWER RESPIRATORY INFECTION
J39.0	RETROPHARYNGEAL AND PARAPHARYNGEAL ABSCESS
J39.1	OTHER ABSCESS OF PHARYNX
J39.2	OTHER DISEASES OF PHARYNX
J39.8	OTHER SPECIFIED DISEASES OF UPPER RESPIRATORY TRACT
J80	ACUTE RESPIRATORY DISTRESS SYNDROME
J96.00	ACUTE RESPIRATORY FAILURE, UNSP W HYPOXIA OR HYPERCAPNIA
J96.01	ACUTE RESPIRATORY FAILURE WITH HYPOXIA
196.02	ACUTE RESPIRATORY FAILURE WITH HYPERCAPNIA
J96.10	CHRONIC RESPIRATORY FAILURE, UNSP W HYPOXIA OR HYPERCAPNIA
J96 11	CHRONIC RESPIRATORY FAILURE WITH HYPOXIA
196.12	CHRONIC RESPIRATORY FAILURE WITH HYPERCAPNIA
196.20	ACUTE AND CHR RESP FAILURE UNSP W HYPOYIA OR HYPERCAPNIA
196.20	ACUTE AND CHRONIC RESPIRATORY FAILURE WITH HYPOXIA
106.22	
J96.22	ACUTE AND CHKONIC KESPIKATOKY FAILUKE WITH HYPEKCAPNIA

J96.90	RESPIRATORY FAILURE, UNSP, UNSP W HYPOXIA OR HYPERCAPNIA
J96.91	RESPIRATORY FAILURE, UNSPECIFIED WITH HYPOXIA
J96.92	RESPIRATORY FAILURE, UNSPECIFIED WITH HYPERCAPNIA
M35.81	MULTISYSTEM INFLAMATORY SYNDROME
M35.89	OTHER SPECIFIED SYSTEMIC INVOLVMENT OF CONNECTIVE TISSUE
R05.1	ACUTE COUGH
R05.3	CHRONIC COUGH
R05.4	COUGH SYNCOPE
R05.8	OTHER SPECIFIED COUGH
R05.9	COUGH, UNSPECIFIED
R09.2	RESPIRATORY ARREST
R50.9	FEVER, UNSPECIFIED
U07.1	COVID-19

Approach to medical chart review validation of hospital admissions

Summary

Chart reviews focused on the elimination of hospitalizations that are clearly not for COVID-19 from analysis (e.g., hospitalizations with incidental SARS-CoV-2 infection that did not contribute to the need for hospitalization and, therefore, do not reflect severe COVID-19 disease). Extensive chart review is not required in most cases.

Most cases are clearly for COVID-19 or for another etiology with only incidental SARS-CoV-2 infection. Therefore, most chart reviews can be limited to:

- 1.) Discharge summary and/or
- 2.) ED note, Admission H&P

However, some cases require more nuanced review and are referred to the MD co-investigator for more detailed review.

- 3.) Discharge summary
- 4.) ED note, Admission H&P
- 5.) Progress notes in limited number of cases
- 6.) Nursing and other notes in rare cases

Definitions

1.) Clearly COVID-19 associated:

a. severe respiratory illness [e.g., acute hypoxemic respiratory failure], severe vomiting and/or diarrhea, or very poor intake with dehydration associated with severe electrolyte disturbance, AKI etc resulting in admission and SARS-CoV-2 positive)

2.) Possibly or likely COVID-19 associated admission:

a. Thromboembolic event (stroke, AMI, PE, DVT) during or shortly after SARS-CoV-2 infection: possible versus likely depends on presence or absence of predisposing

comorbidities (eg., history of stroke, AMI, PE, diabetes, smoking, BCP, etc) and member characteristics (e.g., age)

- b. Cardiac dysrhythmia during or shortly after SARS-CoV-2 infection: probability depends on prior history of dysrhythmia, dysrhythmia-free interval prior to admission, etc.
- c. Members infected with SARS-CoV-2 and another respiratory pathogen that may be associated with similar symptoms may be COVID-19 associated since it is not possible to determine the relative contribution of each pathogen to the symptoms.

3.) Unlikely COVID-19 associated:

- a. incidentally SARS-CoV-2 positive admitted for an unrelated reason (e.g., L&D, elective surgery, baceterial infection such as abscess, cellulitis, etc) without evidence of COVID-19 associated symptoms that would have resulted in admission
- b. admitted for a condition that may be COVID-19 associated (e.g., stroke, cardiac dysrhythmia) but has history of frequent strokes, underlying dysrhythmia, make it less likely that the admission is COVID-19 associated.

Table S2. Risk of COVID-19 outcome among those who received a BNT162b2 XBB1.5-adapted vaccine by comparison and age group among adults ≥18 years of age

Comparison (reference) and age groups	Hospitalization	ED/UC encounter	Outpatient visit
	Adjusted Odds ratio (95% CI)*		
No XBB1.5-adapted vaccine			
≥18 years	0.37 (0.20-0.67)	0.42 (0.34–0.53)	0.42 (0.27-0.66)
18-64 years	0.32 (0.04–2.48)	0.36 (0.24–0.54)	0.68 (0.46–1.01)
≥65 years	0.37 (0.20-0.69)	0.45 (0.34–0.59)	0.32 (0.21-0.51)
BA.4/5-adapted bivalent vaccine but no XBB1.5-adapted vaccine			
≥18 years	0.40 (0.21-0.75)	0.43 (0.34–0.55)	0.49 (0.35-0.68)
18-64 years	0.35 (0.04–2.99)	0.40 (0.26-0.62)	0.78 (0.50-1.21)
≥65 years	0.39 (0.20-0.76)	0.43 (0.31-0.58)	0.29 (0.18-0.47)
≥3 doses of wild-type vaccine but no variant- adapted vaccines of any kind (e.g., XBB1.5- adapted or BA.4/5-adapted or BA.1-adapted bivalent vaccines)			
≥18 years	0.36 (0.20-0.65)	0.41 (0.33-0.51)	0.44 (0.33-0.60)
18-64 years	0.27 (0.03–2.14)	0.34 (0.23–0.51)	0.60 (0.40-0.90)
≥65 years	0.36 (0.19-0.68)	0.45 (0.34–0.60)	0.35 (0.22-0.55)
≥2 doses of wild-type vaccine but no variant- adapted vaccines of any kind (e.g., XBB1.5- adapted or BA.4/5-adapted or BA.1-adapted bivalent vaccines)			
≥18 years	0.37 (0.20-0.67)	0.42 (0.33-0.52)	0.46 (0.34-0.62)
18-64 years	0.30 (0.04–2.32)	0.35 (0.23-0.52)	0.65 (0.43-0.97)
≥65 years	0.37 (0.20-0.70)	0.46 (0.35-0.61)	0.33 (0.21-0.53)
Unvaccinated			
≥18 years	0.32 (0.16-0.64)	0.40 (0.31-0.52)	0.57 (0.39-0.84)
18-64 years	0.37 (0.04-3.22)	0.37 (0.24–0.56)	0.83 (0.52–1.33)
≥65 years	0.29 (0.14-0.61)	0.33 (0.22–0.49)	0.40 (0.18-0.87)

*Models adjusted for week of encounter, age, sex, self-reported race/ethnicity, BMI, Charlson comorbidity index, prior SARS-CoV-2 infection, and utilization history (flu and pneumococcal vaccination, inpatient, ED, and outpatient encounters in prior year). BMI not included in hospitalization models for age <65 due to convergence issues.

Table S3. Risk of COVID-19 outcome among those who received only prior (non-XBB1.5-adapted) vaccine doses compared to the unvaccinated among adults ≥18 years of age, by age group

COVID-19 vaccination status (vs unvaccinated)	Hospitalization	ED/UC encounter	Outpatient visit
	Adjusted Odds ratio (95% CI)*		
BA.4/5-adapted bivalent vaccine but no XBB1.5-adapted vaccine			
≥18 years	0.78 (0.50-1.20)	0.92 (0.76–1.10)	1.18 (0.88–1.56)
18-64 years	1.08 (0.41-2.90)	0.90 (0.72-1.13)	1.01 (0.73–1.41)
≥65 years	0.71 (0.43–1.17)	0.77 (0.56-1.08)	1.42 (0.71–2.83)
≥3 doses of original wild-type vaccine but no variant-adapted vaccines of any kind (e.g., XBB1.5-adapted or BA.4/5- adapted or BA.1-adapted bivalent vaccines)			
≥18 years	0.89 (0.61–1.32)	0.98 (0.84–1.14)	1.36 (1.06–1.74)
18-64 years	1.34 (0.60–3.01)	1.07 (0.89–1.27)	1.38 (1.06–1.81)
≥65 years	0.79 (0.50–1.24)	0.73 (0.54–0.99)	1.15 (0.59–2.24)
≥2 doses of wild-type vaccine but no variant-adapted vaccines of any kind (e.g., XBB1.5- adapted or BA.4/5-adapted or BA.1-adapted bivalent vaccines)			
≥18 years	0.84 (0.57-1.22)	0.96 (0.83–1.11)	1.24 (0.98–1.58)
18-64 years	1.21 (0.56–2.63)	1.04 (0.88–1.22)	1.22 (0.94–1.59)
≥65 years	0.74 (0.48–1.15)	0.71 (0.53–0.96)	1.23 (0.64–2.37)

*Models adjusted for week of encounter, age, sex, self-reported race/ethnicity, BMI, Charlson comorbidity index, prior SARS-CoV-2 infection, and utilization history (flu and pneumococcal vaccination, inpatient, ED, and outpatient encounters in prior year). BMI not included in hospitalization models for age <65 due to convergence issues.

Table S4. Sensitivity analyses of the risk of COVID-19 outcome among those who received a BNT162b2 XBB1.5-adapted vaccine by comparison group among adults ≥18 years of age, including those who received antiviral or monoclonal antibody treatment* in the 30 days prior to their COVID-19 encounter

Comparison (reference) group	Hospitalization	ED/UC encounter	Outpatient visit
	Adjusted Odds ratio (95% CI)**		
No XBB1.5-adapted vaccine	0.36 (0.20-0.66)	0.44 (0.37–0.53)	0.53 (0.41–0.68)
BA.4/5-adapted bivalent vaccine but no XBB1.5-adapted vaccine	0.39 (0.21–0.72)	0.44 (0.36–0.54)	0.54 (0.41–0.72)
≥3 doses of wild-type vaccine but no variant-adapted vaccines of any kind (e.g., XBB1.5- adapted or BA.4/5-adapted or BA.1-adapted bivalent vaccines)	0.35 (0.19–0.63)	0.43 (0.36–0.52)	0.49 (0.38–0.64)
≥2 doses of wild-type vaccine but no variant-adapted vaccines of any kind (e.g., XBB1.5- adapted or BA.4/5-adapted or BA.1-adapted bivalent vaccines)	0.36 (0.20–0.65)	0.44 (0.36–0.53)	0.51 (0.39–0.67)
Unvaccinated	0.32 (0.16-0.65)	0.45 (0.36-0.57)	0.73 (0.52–1.03)

* Nirmatrelvir/ritonavir or any other COVID-19 outpatient antiviral or monoclonal antibody (i.e., molnupiravir, remdesivir, bebtelovimab, bamlanivimab, casirivimab, cilgavimab, sotrovimab, tixagevimab

**Models adjusted for week of encounter, age, sex, self-reported race/ethnicity, BMI, Charlson comorbidity index, prior SARS-CoV-2 infection, and utilization history (flu and pneumococcal vaccination, inpatient, ED, and outpatient encounters in prior year).